Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28003183 | 0.98 | ALDH1A1 (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER | |
| SCHEMBL1571317 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KDM4ESMN1; SMN2EGFRNPC1 | |
| Hydrochloric Acid SCHEMBL28007029 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRNPC1 | |
| SCHEMBL29235188 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER | |
| SCHEMBL12361591 | 0.80 | EGFR (0.59) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER | |
| SCHEMBL27766565 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL28282206 | 0.79 | EGFR (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER | |
| SCHEMBL30979897 | 0.79 | EGFR (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRHPGDS | |
| SCHEMBL28280976 | 0.79 | EGFR (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER | |
| SCHEMBL1632721 | 0.79 | EGFR (0.57) | ALDH1A1KDM4ESMN1; SMN2EGFRGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109999039-A | Quinazoline-THF- the amine of halogenation as PDE1 inhibitor | H.隆德贝克有限公司 | 2019-07-12 | — | — | CN | claimed |
| CN-106132953-B | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H.隆德贝克有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-109999039-A | Quinazoline-THF- the amine of halogenation as PDE1 inhibitor | H.隆德贝克有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-108659005-B | Quinazoline derivatives as EGFR inhibitors | 南京明德新药研发股份有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-108640928-B | Quinazoline compounds as EGFR inhibitor | 南京明德新药研发股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109694356-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-109694355-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-109694370-A | The synthetic method of N- (3- alkynyl phenyl) -4,6- diamino quinazolines compounds and related intermediate | 和记黄埔医药（上海）有限公司 | 2019-04-30 | — | — | CN | disclosed |
| CN-106132953-B | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H.隆德贝克有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-108659005-A | Quinazoline derivatives as EGFR inhibitors | 南京明德新药研发股份有限公司 | 2018-10-16 | — | — | CN | disclosed |
| CN-108640928-A | Quinazoline compounds as EGFR inhibitor | 南京明德新药研发股份有限公司 | 2018-10-12 | — | — | CN | disclosed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | ALDH1A1 2679/4885KDM4E 1007/4885SMN1; SMN2 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.